42 results about "Osmotic pump" patented technology

The present invention discloses a tofacitinib citrate sustained-release tablet preparation and a preparation method thereof, which belongs to the technical field of pharmaceutical preparations. The sustained-release tablet comprises a double-layer core and a coating layer; the double-layer core comprises a drug-containing layer and a push layer; wherein the drug-containing layer comprises: tofacitinib citrate, an adhesive, polyethylene oxide, a glidant and a lubricant; the push layer comprises: mannitol, an adhesive, red iron oxide, polyethylene oxide, a glidant and a lubricant; the coating layer comprises: cellulose acetate, a pore-forming agent, a plasticizer, water and acetone. The sustained-release tablet preparation of the present invention solves the technical problems existing in the prior art by adopting a double-layer osmotic pump prescription design, adopting non-hygroscopic materials such as mannitol, adopting a standard round tablet design, preparing a sustained-release coating layer without using methanol, and adopting a coating machine for coating and curing.

The invention relates to the technical field of drug delivery systems. The invention provides an osmotic pump drug release system based on a fenerenone solid dispersion and a preparation method of the osmotic pump drug release system. According to the fenerenone solid dispersion prepared by adopting a hot melt extrusion technology and the osmotic pump drug release system based on the fenerenone solid dispersion, the solubility and the bioavailability of the fenerenone in the solid dispersion can be improved, and drug absorption can be accelerated; the sustained and stable release of the fenerenone can be realized, the drug release rate is optimized, the effectiveness and safety of the drug in the treatment process are ensured, the chemical stability of the fenerenone is improved, and the validity period of the drug is prolonged. Various challenges of the fenerenone in the using process are effectively solved, a more effective and safer treatment scheme is provided for patients suffering from chronic kidney diseases complicated with type 2 diabetes, and important practical value and wide market prospects are achieved.

The invention relates to the technical field of pharmaceutical preparations, in particular to a rapamycin multiphase release or osmotic pump type weekly-effect oral controlled-release composition and a preparation method thereof, and the rapamycin multiphase release or osmotic pump type weekly-effect oral controlled-release composition comprises a quick release layer, a slow release layer and an osmotic pump structural design. According to the application, staged or constant-rate release of rapamycin within 168 hours is realized through a multi-phase release technology or an osmotic pump technology, and the problems that an existing preparation is large in blood concentration fluctuation, high in administration frequency and low in bioavailability are solved. The composition is suitable for treating hypertrophic cardiomyopathy of cats, significantly improves cardiac functions and reduces side effects and risks, is administered once a week, and is convenient to use. The invention further provides a storage method, and the product stability is ensured. The technical scheme has remarkable clinical advantages and application prospects.

A water treatment plant or system for the production of permeate includes a reverse osmosis stage and a permeate stage. The reverse osmosis stage can include a piping system having a supply line for process input water, a reverse osmosis pump, and a reverse osmosis tank. The reverse osmosis tank has an inlet for process input water coming from the reverse osmosis pump, a membrane, and an outlet for permeate. The permeate stage, which can have a line system forming a circuit, can include a permeate tank, a permeate pump, and a tapping point for connecting at least one consumer or user of permeate. The reverse osmosis stage and the permeate stage can be connected to one another via a connecting line in such a way that the reverse osmosis stage feeds the permeate stage with permeate. The circuit of the permeate stage can include a sterile filter.

The invention discloses a topiromilast osmotic pump tablet and a preparation method thereof. The topiromilast osmotic pump tablet comprises a tablet core composed of a drug layer and a pushing layer, a semipermeable membrane coating outside the tablet core, and a single drug release small hole and an isolation coating on the surface of a controlled release tablet on one side of the drug layer. Compared with topiromilast tablets on the market at present, the topiromilast osmotic pump controlled release tablet prepared by the invention can realize continuous and stable constant-speed release of drugs. After a patient takes the medicine, the medicine in the medicine release layer cannot be released immediately, and the tablet can rhythmically release the medicine, maintain the steady-state blood concentration, delay the peak time and prolong the half-life period of the medicine within more than ten subsequent hours under the action of the pushing layer, so that the bioavailability is improved, and the slow release effect of more than 12 hours is achieved. Due to the adoption of a double-layer osmotic pump controlled release technology, compared with a single-layer tablet, the double-layer osmotic pump controlled release tablet has the advantages of stronger controllability, more complete release and higher availability.

An osmotic pump controlled-release tablet of an insoluble drug includes a tablet core, a semi-permeable membrane coating and a drug-release hole, wherein the tablet core includes a solid dispersion of the insoluble drug and a penetration enhancer, the solid dispersion of the insoluble drug includes the insoluble drug and a carrier, the insoluble drug is selected from nicardipine, nifedipine and felodipine and pharmaceutically acceptable salts thereof, and the carrier is selected from organic acids. Compared with other tablets, the drug solubility of the osmotic pump controlled-release tablet of the insoluble drug is improved, a large amount of penetration enhancers or other excipients do not need to be used in the tablet core, the drug-loading capacity is improved, and the tablet core is not too large; the degree of release in vivo is improved.

An electro-osmotic pump according to an embodiment of the present disclosure includes: a membrane that allows fluid movement; and a first electrode and a second electrode respectively provided on both sides of the membrane. The first electrode and the second electrode are formed of an impermeable substrate material and an electrode material coated thereon and have at least one fluid pathway. The impermeable substrate material is a plate-shaped substrate including at least one of a conducting material, a semiconducing material and a non-conducting material.

Main requirement: Water treatment plant for the production of permeate, especially for dialysis therapy, comprising • a reverse osmosis stage (137) with a piping system comprising a supply line (131) for process inlet water (100), a reverse osmosis pump (103) and a reverse osmosis tank (130), wherein the reverse osmosis tank (130) has an inlet (143) for the process inlet water (100) coming from the reverse osmosis pump (103), a membrane (104) and an outlet (144) for permeate (108), • a permeate stage (139) with a circulating piping system comprising a permeate tank (112), a permeate pump (114) and a take-off point (134) for connecting at least one consumer or user of permeate (108), wherein the reverse osmosis stage (137) and the permeate stage (139) are connected to each other via a connecting line (138) such that the reverse osmosis stage (137) feeds the permeate stage (139) with permeate (108), and wherein the circuit of the permeate stage (138) comprises a sterile filter (116).

The invention provides a nicotine osmotic pump tablet and a preparation method thereof, the nicotine osmotic pump tablet is suitable for the oral cavity, the nicotine osmotic pump tablet comprises a tablet core, the tablet core comprises a drug-containing layer and a boosting layer, the drug-containing layer contains nicotine, and the ratio of the viscosity of the drug-containing layer to the viscosity of the boosting layer is 1: 1.5-1: 2; the tablet core is coated with the semi-permeable membrane; and the release hole can release nicotine after the semipermeable membrane permeates into the liquid. By adopting the nicotine osmotic pump tablet, nicotine is released at an approximately constant rate, the problems that oral mucosa and even stomach are stimulated to cause nausea and the like due to too fast release of nicotine are avoided, and meanwhile, sticky feeling or foreign body sensation is avoided during oral administration.

The application provides a tivozanib hydrochloride osmotic pump controlled-release tablet, which is characterized in that the tablet comprises a tablet core, and the tablet core comprises 100 parts of tivozanib hydrochloride, 30-60 parts of a retarder, 40-80 parts of a disintegrant and / or an osmotic pressure promoter, 40-90 parts of a cosolvent and 8-15 parts of a pore-forming agent in terms of weight fraction. The tivozanib hydrochloride osmotic pump controlled-release tablet can realize zero-order release and has a 24-hour cumulative release degree of more than 96%, so that the bioavailability of tivozanib in vivo is improved, and the frequency or dosage of oral solid preparations of tivozanib is reduced.

The invention relates to a detachable multi-organ chip co-culture device, and relates to the technical field of biological tissue engineering. Comprising an upper-layer fluid channel layer chip, a lower-layer micro-pit cell culture layer chip and an osmotic pump, the upper-layer fluid channel layer chip and the lower-layer micro-pit cell culture layer chip are respectively divided into five independent functional units, and the structures of the independent functional units are mutually independent; each independent functional unit of the upper fluid channel layer chip comprises a fluid channel structure; each independent functional unit of the lower-layer micro-pit cell culture layer chip comprises a micro-pit array structure and a micro-cavity, and the micro-pit array structure is arranged at the bottom of the micro-cavity; the upper-layer fluid channel layer chip and the lower-layer micro-pit cell culture layer chip are detachably combined and connected through a tenon-and-mortise structure; the osmotic pump is connected to the outlet end of the culture device and is used for constructing a dynamic perfusion culture environment. According to the invention, high-throughput culture of multiple organs can be realized, and the cell viability and proliferation state are good under a dynamic perfusion condition.

An osmotic pump tablet, its preparation method and use. The osmotic pump tablet comprises a tablet core and a coating film wrapping the tablet core, the coating film has a drug release hole, the tablet core comprises a drug-containing layer, the drug-containing layer comprises a drug active ingredient, a hydrophilic polymer and a surfactant, the hydrophilic polymer comprises hydroxypropyl cellulose and the surfactant comprises poloxamer; or the drug-containing layer comprises a drug active ingredient and a hydrophilic polymer but does not contain a surfactant; the hydrophilic polymer comprises povidone K29 / 32; or the osmotic pump tablet comprises a drug-containing immediate-release outer coating, the drug-containing immediate-release outer coating comprises a drug active ingredient and a pharmaceutical excipient, and the pharmaceutical excipient is a binder.

In some example embodiments, there may provided a system that includes an osmotic pump; a fluidics structure coupled to the osmotic pump, and at least one sensor configured to measure a concentration of at least a first analyte in a biofluid collected using the system.

The invention relates to an osmotic pump tablet as well as a preparation method and application thereof. The osmotic pump tablet comprises a tablet core and a coating film wrapping the tablet core, the coating film is provided with drug release holes, the tablet core comprises a drug-containing layer, the drug-containing layer comprises active pharmaceutical ingredients, a hydrophilic polymer and a surfactant, the hydrophilic polymer comprises hydroxypropyl cellulose, and the surfactant comprises poloxamer; or the drug-containing layer comprises a drug active ingredient and a hydrophilic polymer, but does not contain a surfactant; the hydrophilic polymer is prepared from povidone K29 / 32; or the osmotic pump tablet contains the drug-containing quick-release outer coating, the drug-containing quick-release outer coating contains the active pharmaceutical ingredient and the pharmaceutic adjuvant, and the pharmaceutic adjuvant is an adhesive. The invention further provides a preparation method and application of the compound. The osmotic pump tablet disclosed by the invention is high in drug loading capacity and can well play a treatment effect.

The invention relates to a nicotine osmotic pump tablet for oral cavity and a preparation method thereof. The nicotine osmotic pump tablet for the oral cavity comprises a tablet core, the tablet core comprises a medicine layer and a boosting layer, the medicine layer comprises nicotine and a hydrophilic polymer, and the boosting layer comprises an osmotic pressure accelerant, an insoluble expanding agent and a hydrophilic polymer; the semipermeable membrane covers the tablet core, the weight of the semipermeable membrane accounts for less than 10% of the weight of the tablet core, the semipermeable membrane comprises a base material and a pore-foaming agent, and the weight of the pore-foaming agent accounts for 10%-20% of the weight of the semipermeable membrane; and the release hole can release the nicotine after the semipermeable membrane permeates into the liquid. The nicotine osmotic pump tablet for the oral cavity can adapt to the oral cavity environment, meets the core requirement of applying nicotine to the oral cavity, has no rupture condition in the nicotine dissolution process, is better in mechanical property, and can be accurately, rapidly and completely released in the oral cavity environment in a short time in a staged manner.

The invention discloses a preparation method of a theophylline controlled-release tablet and the theophylline controlled-release tablet. The preparation method comprises the following steps: S1, dry granulation of a medicine layer: preparing medicine layer particles from theophylline, a slow-release hydrophilic polymer material, a moisture absorbent, a flow aid and a lubricant; s2, performing dry granulation on the boosting layer: preparing boosting layer particles from a coloring material, an expansive high polymer material, a moisture absorbent, a flow aid and a lubricant; s3, tabletting of double-layer tablets: adding the medicine layer particles and the boosting layer particles into a double-layer tablet press for tabletting; s4, semi-permeable membrane coating: adding the theophylline double-layer tablet chip and a semi-permeable membrane coating solution into a coating machine; and S5, laser drilling: drilling holes in the theophylline double-layer semi-permeable membrane coating tablets through a laser drilling machine. The osmotic pump controlled release technology is utilized to control the constant-speed release of the medicine, the medicine effect is more lasting, the plasma concentration is stable, the adverse reaction of the medicine is effectively reduced, the medicine taking frequency is reduced, the medicine taking compliance of a patient is improved, and the clinical treatment effect of the medicine is improved.

Main claim: Water treatment plant for the production of permeate, in particular for dialysis therapy, comprising: • a reverse osmosis stage (137) with a piping system comprising a supply line (131) for process inlet water (100), a reverse osmosis pump (103) and a reverse osmosis tank (130), wherein the reverse osmosis tank (130) has an inlet (143) for the process inlet water (100) coming from the reverse osmosis pump (103), a membrane (104) and an outlet (144) for permeate (108), • a permeate stage (139) with a circulating piping system comprising a permeate tank (112), a permeate pump (114) and a discharge point (134) for connecting at least one consumer or user of permeate (108), wherein the reverse osmosis stage (137) and the permeate stage (139) are connected to each other via a connecting line (138) such that the reverse osmosis stage (137) feeds the permeate stage (139) with permeate (108),and wherein the permeate stage circuit (138) includes a sterile filter (116).

The utility model provides a cabinet type high-speed osmotic pump laser-beam drilling machine, which relates to the technical field of laser-beam drilling machines, and comprises a cabinet body, the top of the cabinet body is fixedly connected with a workbench close to the center, and the top of the workbench is fixedly provided with a protective cover along the peripheral direction. Sliding grooves are formed in the edges of the two sides of the outer surface of the front side of the protective cover, sliding doors are slidably connected into the two sliding grooves, the sliding doors are connected with the protective cover in a matched mode, and fixing blocks are fixedly connected to the edges, close to the opposite sides, of the outer surfaces of the front sides of the two sliding doors. The laser-beam drilling machine solves the problems that when a traditional laser-beam drilling machine is used for drilling, strong light stimulation exists, irritant harm is generated to eyes, certain safety danger exists when the device is used, the using effect of the device is reduced, and the using cost of the device is reduced. And when an existing laser-beam drilling machine conducts drilling, calibration drilling is needed one by one, time is wasted, and the use efficiency of the device is reduced.

A biological treatment system comprising: a treatment vessel; a plurality of filter housings; a feed pump for moving fluid between the processing vessel and the filtration assembly; and a retention valve within the retention line. The retention valve includes a fluid passage to selectively direct movement of a fluid to at least one of the plurality of filter housings; an osmotic valve is arranged in the osmotic pipeline between the filter shell and the osmotic pump; a pressure sensor disposed in the permeate line, and a controller coupled to the pressure sensor, the retention valve, and the permeate valve. A controller actuates the retention valve and the osmotic valve to direct flow between the processing vessel and the one or more filter housings based on information received from the flow sensor and the pressure sensor, and direct osmotic flow from the filter housings to the osmotic pump.

The present application relates to a kind of poorly soluble drug osmotic pump controlled-release tablets and its preparation method, the osmotic pump controlled-release tablets include tablet core, semi-permeable membrane coating and release hole, the tablet core includes solid dispersion of poorly soluble drug and penetration agent, the solid dispersion of poorly soluble drug includes poorly soluble drug and carrier, the poorly soluble drug is selected from nicardipine, nifedipine, felodipine and their pharmaceutically acceptable salt, the carrier is selected from organic acid substance.Compared with prior art, the poorly soluble drug osmotic pump controlled-release tablets of the present application greatly improves the drug solubility, without using a large amount of penetration agent or other excipients in tablet core, drug loading is increased, and tablet core will not be too large;In vivo release greatly improves;Preparation process is simple, equipment requirement and cost are low, and easy to industrialization.

The invention discloses a gentiopicroside microporous osmotic pump tablet and a preparation method thereof, and the preparation method comprises the following steps: 1) preparing a medicine-containing tablet core: weighing 40-50% of gentiopicroside, 20-30% of osmotic pressure active substance, 20-39% of filler and 1-2% of lubricant according to weight ratio, granulating and tabletting to obtain the medicine-containing tablet core; 2) preparing a coating solution: weighing 2%-4% of ethyl cellulose, 0.2% of a plasticizer and 1%-3% of a pore-foaming agent according to a weight ratio, and dissolving in an organic solvent to prepare the coating solution; and 3) coating, wherein the weight of the coating is increased by 5-15% of the weight of the tablet-containing core. According to the gentiopicroside microporous osmotic pump tablet disclosed by the invention, the coating film controls the release of the medicine, the permeability of the coating film is changed by adding the pore-foaming agent, so that the medicine is released from the coating film, and the dosage of the pore-foaming agent determines the medicine release rate; according to the dosage form, the retention time of gentiopicroside in the body can be prolonged, and the treatment effect of gentiopicroside can be fully exerted.

The present application provides a kind of felodipine osmotic pump controlled-release tablets and preparation method thereof, the osmotic pump controlled-release tablet is composed of osmotic pump controlled-release tablet core and water-insoluble coating layer (single side laser punching), the weight percentage of the felodipine osmotic pump controlled-release tablet contains immediate-release coating layer, controlled-release coating layer, propelling coating layer, water-insoluble coating layer is (5~20) :(5~30) :(10~50) :(5~30).The present application also provides a kind of preparation method of felodipine osmotic pump controlled-release tablet and its application in treating hypertension.The formulation of the felodipine osmotic pump controlled-release tablet of the present application is reasonable, and production process is simple and easy to control;By replacing traditional controlled-release tablet polyethylene oxide with different povidone, the controllability of felodipine osmotic pump controlled-release tablet preparation is significantly improved, and the difficulty of cleaning in production is reduced.

The invention relates to a water treatment device for producing a permeate, in particular for dialysis treatments, comprising: a reverse osmosis stage having a line system comprising an input line for process input water, a reverse osmosis pump and a reverse osmosis container, wherein the reverse osmosis vessel has an inlet for process input water from a reverse osmosis pump, a membrane and an outlet for permeate; the invention relates to a reverse osmosis system comprising a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage and a reverse osmosis stage, the reverse osmosis stage supplies permeate to the permeate stage, and wherein the loop of the permeate stage comprises a sterile filter.

The utility model relates to the technical field of water treatment, in particular to a highly integrated pure water treatment device which comprises an integrated frame, a precision filter, a water inlet header pipe, a first-stage reverse osmosis pump, a first-stage RO membrane, a second-stage reverse osmosis pump and a second-stage RO membrane are arranged in the integrated frame, an inlet of the precision filter is communicated with the water inlet header pipe, and an outlet of the precision filter is communicated with the water inlet header pipe. An outlet of the precision filter is connected with a first-stage reverse osmosis pump, an outlet of the first-stage reverse osmosis pump is connected with a first-stage RO membrane, a concentrated water outlet of the first-stage RO membrane is communicated to a trench through a pipeline, a pure water outlet of the first-stage RO membrane is connected with a second-stage reverse osmosis pump, and an outlet of the second-stage reverse osmosis pump is communicated with a second-stage RO membrane; a pure water outlet of the second-stage RO membrane is connected between the first-stage RO pump and the water inlet header pipe through a pipeline, a pure water outlet of the second-stage RO membrane is connected to the pure water tank through a water pipe, and a control system is arranged in the integrated frame, so that the effects that the occupied space of the pure water treatment device is smaller, and the pure water preparation rate is higher are achieved.

The invention discloses a citric acid tofacitinib osmotic pump sustained-release tablet, which comprises a citric acid tofacitinib tablet core and a sustained-release coating layer coated on the surface of the citric acid tofacitinib tablet core, the citric acid tofacitinib tablet core contains a waxy framework material, and the sustained-release coating layer contains a sustained-release membrane material and a pore-foaming agent; the slow-release membrane material is composed of eudragit RL and eudragit RS; the pore-foaming agent is a water-soluble pore-foaming agent. The invention also discloses a preparation method of the tofacitinib citrate osmotic pump sustained release tablet, which comprises the following steps: uniformly mixing the components of the tablet core, and tabletting to obtain the tablet core; coating the tablet core, preserving heat and curing to obtain the tofacitinib citrate osmotic pump sustained release tablet. According to the invention, the corrosion controlled release of the waxy framework material and the controlled release coating layer are hierarchically coupled, so that the drug release stability is obviously improved, the tolerance to the change of the gastrointestinal tract physiological environment is stronger, and the dissolution of the drug is not reduced after long-term storage.

The invention discloses an oral abutment with a drug sustained release function, and relates to the technical field of medical implantation. In order to solve the problem of poor treatment effect caused by insufficient drug concentration in the prior art, the invention designs the oral cavity abutment with the drug sustained-release function, and the oral cavity abutment is mainly structurally characterized by having three drug release modes which are mutually matched and linked; comprising a continuous release mode structure, an inflammation release mode structure and a stress release mode structure, in a daily state, a proper amount of medicine is continuously released through an osmotic pump, and the basic treatment concentration is maintained; after the mucosa around the implant is inflamed, the temperature rise of the inflammation part is detected, and the medicine release amount is increased through an inflammation release mode structure so as to strengthen the treatment effect; when a patient presses and occludes, the drug release amount is further supplemented through the stress release mode structure. According to the invention, the treatment effect on the mucositis around the implant is obviously improved, and the repair and regeneration of tissues around the implant are promoted.

The invention discloses an isosorbide mononitrate osmotic pump controlled-release tablet and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. An isosorbide mononitrate osmotic pump controlled-release tablet of the invention comprises a booster layer, wherein drug-containing layers are arranged above and below the booster layer, and the booster layer and the drug-containing layer are wrapped with a semipermeable membrane coating layer, and the semipermeable membrane coating layer is provided with drug-releasing holes. The isosorbide mononitrate osmotic pump controlled-release tablet of the invention has a three-layer tablet core structure of "drug-containing layer-boosting layer-drug-containing layer", and drug-releasing holes are provided in the semipermeable membrane coating layer to achieve a sustained-release effect, so that the dissolution amount increases slowly, the sustained-release effect is good, the release is stable, the effect is long-lasting, and multiple administrations can be avoided.

The present disclosure relates to an osmotic pump tablet, preparation method therefor and use thereof. The osmotic pump tablet comprises a tablet core and a coating membrane that wraps around the tablet core, with a drug-release orifice in the coating membrane. The tablet core includes a drug-containing layer, which contains an active pharmaceutical ingredient, a hydrophilic polymer, and a surfactant. The hydrophilic polymer includes hydroxypropyl cellulose, and the surfactant includes poloxamer; or the drug-containing layer contains an active pharmaceutical ingredient and a hydrophilic polymer, but no surfactant. The hydrophilic polymer includes povidone K29 / 32; or the osmotic pump tablet includes a drug-containing immediate release overcoat, which contains an active pharmaceutical ingredient and a pharmaceutical excipient, which is a binding agent. The osmotic pump tablet disclosed herein features high drug loading capacity, enabling it to achieve optimal therapeutic efficacy.

The invention relates to the technical field of sustained-release preparations, and particularly discloses a gentiopicroside sustained-release preparation and a preparation process thereof, and the gentiopicroside sustained-release preparation is technically characterized in that the sustained-release preparation is a microporous osmotic pump tablet or a skeleton sustained-release tablet; the microporous osmotic pump tablet comprises a tablet core and a coating, wherein the tablet core is composed of gentiopicroside and auxiliary materials; the auxiliary materials comprise ethyl cellulose, microcrystalline cellulose, magnesium stearate and 60% ethanol; the coating is composed of ethyl cellulose, PEG 6000, triethyl citrate and ethyl alcohol, and the weight of the coating is increased by 4%-10%. According to the scheme, the problems of short half-life period and short in-vivo time of the gentiopicroside are solved, the gentiopicroside microporous osmotic pump tablet (GPS-MPOP) and the skeleton sustained release tablet (GPS-MRT) are prepared respectively, the in-vitro drug release behavior, the drug release mechanism and in-vivo pharmacokinetics of the gentiopicroside microporous osmotic pump tablet and the skeleton sustained release tablet are studied, and the scheme proves that the release characteristic of the gentiopicroside is remarkably improved, so that the gentiopicroside can be applied to the field of pharmaceutical preparations. And new technical support and theoretical basis are provided for clinical application.

Disclosed in the present invention are a topiroxostat osmotic pump tablet and a preparation method therefor. The topiroxostat osmotic pump tablet comprises: a tablet core consisting of a drug layer and a push layer; a semipermeable membrane coating outside the tablet core; a single drug-release orifice on the controlled-release tablet surface on the side of the drug layer; and an isolation film coating. Compared with topiroxostat tablets currently on the market, the topiroxostat osmotic pump controlled-release tablet prepared in the present invention achieves sustained and stable constant-rate drug release. The drug in a drug-release layer is not released immediately after a patient takes the drug; within the ten or more hours thereafter, the tablet can release the drug rhythmically under the action of the push layer, maintaining a steady-state plasma concentration, delaying the time at which the peak is reached, and prolonging the half-life of the drug, thereby improving bioavailability and achieving a sustained release effect of 12 h or more. Because a dual-layer osmotic pump controlled-release technology is used, the drug has stronger controllability, a more complete release, and higher bioavailability in comparison with single-layer tablets.